1214883-23-4

Upstream product

• 1002127-15-2 ethyl (E)-5,5-dibromo-2,4-pentadienoate 
• 1002128-53-1 (2E,4Z)-5-(4-Ethoxyphenyl)-5-[4-(trifluoromethyl)phenyl]-2,4-pentadienoic acid 
• 1214883-21-2 (3R)-5-amino-3-hydroxy-3,4-dihydroquinolin-2(1H)-one 
• 1002127-25-4 ethyl (2E,4Z)-5-bromo-5-(4-trifluoromethylphenyl)-2,4-pentadienoate 
• 292143-04-5 5-amino-3-hydroxy-3,4-dihydroquinolin-2(1H)-one 

Relevant academic research and scientific papers

Discovery of novel 5,5-diarylpentadienamides as orally available transient receptor potential vanilloid 1 (TRPV1) antagonists

We have developed a novel and potent chemical series of 5,5-diphenylpentadienamides for targeting TRPV1 in vitro and in vivo. In this investigation, we examined a variety of replacements for the 5-position of dienamides with the goal of addressing issues related to pharmacokinetics. Our data suggest that substitution with alkoxy groups on the phenyl ring at the 5-position increases their ability to penetrate the blood-brain barrier. This investigation culminated in the discovery of compound (R)-36b, which showed a good pharmacokinetic profile. In vivo, compound (R)-36b was found to be effective at reversing mechanical allodynia in rats in a dose-dependent manner, and it reversed thermal hyperalgesia in a model of neuropathic pain induced by sciatic nerve injury.